Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 18/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523715 | 0.91 | PGR (0.77) | PGRNR3C1PDE4APDE4BPDE4C | |
| SCHEMBL3519246 | 0.85 | PGR (0.74) | PGR | |
| SCHEMBL6424665 | 0.84 | PGR (0.67) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3520506 | 0.83 | PGR (0.72) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3517961 | 0.82 | PGR (1.00) | PGRNR3C1 | |
| SCHEMBL3521863 | 0.81 | PGR (1.00) | PGRNR3C1 | |
| SCHEMBL6426704 | 0.80 | PGR (0.71) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8273319 | 0.78 | PGR (0.56) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4715658 | 0.78 | PGR (0.59) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3521176 | 0.77 | PGR (0.73) | PGRNR3C1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175398-B1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | WYETH CORP (US) | 2007-07-11 | — | — | EP | claimed |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2003-03-13 | — | — | US | claimed |
| US-6462032-B1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2002-10-08 | — | — | US | claimed |
| US-6391907-B1 | ANTICANCER AGENTS; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-05-21 | — | — | US | claimed |
| US-7645761-B2 | Indoline derivatives | WYETH (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070259944-A1 | Indoline derivatives | WYETH (US) | 2007-11-08 | — | — | US | disclosed |
| US-7253203-B2 | Indoline derivatives | WYETH (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1175398-B1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | WYETH CORP (US) | 2007-07-11 | — | — | EP | disclosed |
| US-7084168-B2 | Indoline derivatives | WYETH (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060160882-A1 | Indoline derivatives | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
| US-20030220388-A1 | Amides such as 5-(3-Nitrophenyl)-1,3-dihydro-indol-2-one, used as antiprogesterones, contraceptives, for hormone replacement therapy during menopause and as anticarcinogenic agents | WYETH | 2003-11-27 | — | — | US | disclosed |
| US-6608068-B2 | Substituted indoline derivative compounds which are antagonists of the progesterone receptor; contraceptives; antineoplastic agents | WYETH | 2003-08-19 | — | — | US | disclosed |
| US-6544970-B2 | Administering in a first phase of a progestational agent (levonorgestrel or ethinylestradiol) and in a second phase an antiprogestin that is an indolinone derivative, especially a 3-spiroalkylene derivative | WYETH | 2003-04-08 | — | — | US | disclosed |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2003-03-13 | — | — | US | disclosed |
| US-6462032-B1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2002-10-08 | — | — | US | disclosed |
| US-20020086874-A1 | Indoline derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-07-04 | — | — | US | disclosed |
| US-6391907-B1 | ANTICANCER AGENTS; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259944-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | PGR 1/4885NR3C1 45/4885PDE4A 2487/4885 |
| US-20020086874-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | PGR 1/4885NR3C1 39/4885PDE4A 3088/4885 |
| US-20060160882-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | PGR 1/4885NR3C1 45/4885PDE4A 2487/4885 |
| US-20030220388-A1 | Amides such as 5-(3-Nitrophenyl)-1,3-dihydro-indol-2-one, used as antiprogesterones, contraceptives, for hormone replacement therapy during menopause and as anticarcinogenic agents | PGR, CYP19A1, PGRMC1 | PGR 1/4885NR3C1 36/4885PDE4A 3203/4885 |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | PRLHR, GNRHR, BRCA1 | PGR 5/4885NR3C1 178/4885PDE4A 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.